HC Wainwright Cuts Repare Therapeutics (NASDAQ:RPTX) Price Target to $5.00

Repare Therapeutics (NASDAQ:RPTX) had its price target trimmed by HC Wainwright from $10.00 to $5.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. Stifel Nicolaus cut their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Finally, Bloom Burton downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th.

Repare Therapeutics Stock Performance

NASDAQ RPTX opened at $1.19 on Friday. The stock has a market capitalization of $50.38 million, a P/E ratio of -0.59 and a beta of 0.87. Repare Therapeutics has a 1 year low of $1.06 and a 1 year high of $6.08. The business’s fifty day moving average is $1.25 and its two-hundred day moving average is $2.41.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. On average, research analysts forecast that Repare Therapeutics will post -2.04 earnings per share for the current year.

Hedge Funds Weigh In On Repare Therapeutics

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC raised its holdings in shares of Repare Therapeutics by 65.5% during the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company’s stock worth $224,000 after acquiring an additional 67,638 shares in the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth $104,000. Blue Owl Capital Holdings LP raised its holdings in shares of Repare Therapeutics by 2.1% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company’s stock worth $4,511,000 after acquiring an additional 71,160 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Repare Therapeutics by 73.1% during the fourth quarter. Stifel Financial Corp now owns 89,500 shares of the company’s stock worth $117,000 after acquiring an additional 37,800 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Repare Therapeutics by 204.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock worth $45,000 after acquiring an additional 23,127 shares in the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.